Suppr超能文献

肺移植受者慢性戊型肝炎病毒感染的病程及治疗

Course and treatment of chronic hepatitis E virus infection in lung transplant recipients.

作者信息

Pischke S, Greer M, Hardtke S, Bremer B, Gisa A, Lehmann P, Haverich A, Welte T, Manns M P, Wedemeyer H, Gottlieb J

机构信息

Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; IFB-TX, Hannover, Germany.

出版信息

Transpl Infect Dis. 2014 Apr;16(2):333-9. doi: 10.1111/tid.12183. Epub 2014 Jan 20.

Abstract

OBJECTIVE

Persistent hepatitis E virus (HEV) infections have been described in various transplant cohorts. However, the frequency and the course of HEV infection in lung transplant recipients (Lu-Tr) are not well defined.

METHODS

We retrospectively analyzed serum from 95 Lu-Tr for HEV RNA and anti-HEV immunoglobulin-G (IgG) (with the MP assay). Anti-HEV seroprevalence was compared to that of 537 healthy individuals. Prospective HEV screening was subsequently initiated in Lu-Tr.

RESULTS

Elevated liver enzymes were observed in 44/95 (46.3%) patients. Anti-HEV IgG was present in 5/95 patients (5.3%), revealing a slightly higher prevalence compared to controls (2%, 11/537; P = 0.07). Chronic HEV infection with detectable viral replication was confirmed by polymerase chain reaction in 3 (3.2%) patients, all of whom demonstrated clinical and biochemical features of active liver disease (maximum alanine aminotransferase [ALTmax ] 89, 215, and 270 IU/L, respectively). One patient had died from multi-organ failure in combination with liver cirrhosis before HEV diagnosis. Two additional patients with chronic hepatitis E were identified during prospective screening (ALTmax 359 and 318 IU/L). All patients still alive commenced ribavirin therapy for 5 months, with dose adjustment (400-600 mg/day) according to renal function and hemoglobin level. Sustained resolution of HEV infection occurred in 2 patients. One patient is still under treatment, and the fourth died from graft failure considered unrelated to ribavirin therapy.

CONCLUSION

Chronic hepatitis E should be considered in the differential diagnosis of elevated liver enzymes, which are commonly seen in Lu-Tr. We observed 1 case of end-stage liver cirrhosis and death in an HEV-infected subject, who was not treated with ribavirin. Given this potentially devastating consequence, ribavirin therapy of persistent HEV infection appears to be acceptably safe and effective in Lu-Tr. However, larger prospective studies are warranted.

摘要

目的

在不同移植队列中均有持续性戊型肝炎病毒(HEV)感染的报道。然而,肺移植受者(Lu-Tr)中HEV感染的频率和病程尚不明确。

方法

我们回顾性分析了95例Lu-Tr受者的血清,检测其中的HEV RNA和抗HEV免疫球蛋白G(IgG)(采用MP检测法)。将抗HEV血清阳性率与537名健康个体进行比较。随后对Lu-Tr受者开展了前瞻性HEV筛查。

结果

95例患者中有44例(46.3%)出现肝酶升高。95例患者中有5例(5.3%)抗HEV IgG呈阳性,其患病率略高于对照组(2%,537例中有11例;P = 0.07)。通过聚合酶链反应证实3例(3.2%)患者存在慢性HEV感染且病毒复制可检测到,所有这些患者均表现出活动性肝病的临床和生化特征(最大丙氨酸转氨酶[ALTmax]分别为89、215和270 IU/L)。1例患者在诊断出HEV之前死于多器官功能衰竭合并肝硬化。在前瞻性筛查期间又发现另外2例慢性戊型肝炎患者(ALTmax分别为359和318 IU/L)。所有仍存活的患者均开始接受为期5个月的利巴韦林治疗,并根据肾功能和血红蛋白水平调整剂量(400 - 600 mg/天)。2例患者的HEV感染得到持续缓解。1例患者仍在接受治疗,第4例患者死于与利巴韦林治疗无关的移植失败。

结论

在Lu-Tr受者中常见的肝酶升高的鉴别诊断中应考虑慢性戊型肝炎。我们观察到1例HEV感染患者出现终末期肝硬化并死亡,该患者未接受利巴韦林治疗。鉴于这种潜在的严重后果,利巴韦林治疗持续性HEV感染在Lu-Tr受者中似乎具有可接受的安全性和有效性。然而,有必要开展更大规模的前瞻性研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验